A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups).
Chemical ID:
MESH:D002945
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
ABCB1 protein inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; ABCB1 protein inhibits the reaction [Cisplatin results in increased activity of and results in increased cleavage of CASP3 protein]; ABCB1 protein inhibits the reaction [Cisplatin results in increased activity of CASP9 protein]; ABCB1 protein promotes the reaction [Cisplatin results in increased expression of TRP53 protein]
[Diethylnitrosamine co-treated with Cisplatin] results in increased expression of ABCB1 protein; Omeprazole promotes the reaction [Cisplatin results in increased expression of ABCB1A protein]
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of ABCB1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of ABCB1 protein; [Cisplatin results in decreased susceptibility to Cisplatin] which results in increased expression of ABCB1 mRNA; [Cisplatin results in increased acetylation of APEX1 protein] promotes the reaction [[APEX1 protein modified form binds to ABCB1 promoter] which results in increased expression of ABCB1 mRNA]; [Cisplatin results in increased acetylation of APEX1 protein] promotes the reaction [APEX1 protein modified form binds to ABCB1 promoter]; [CXCL8 results in increased expression of ABCB1 mRNA] which results in decreased susceptibility to Cisplatin; [CXCL8 results in increased expression of ABCB1 protein] which results in decreased susceptibility to Cisplatin; [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Cisplatin; ABCB1 affects the reaction [HIF1A affects the susceptibility to Cisplatin]; ABCB1 gene SNP affects the susceptibility to [Cisplatin co-treated with Fluorouracil]; ABCB1 protein inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; ABCB1 protein inhibits the reaction [Cisplatin results in increased activity of and results in increased cleavage of CASP3 protein]; ABCB1 protein inhibits the reaction [Cisplatin results in increased activity of CASP9 protein]; ABCB1 protein promotes the reaction [Cisplatin results in increased expression of TRP53 protein]; Chloroquine promotes the reaction [Cisplatin results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Cisplatin results in decreased expression of ABCB1 protein]; Cisplatin promotes the reaction [[APEX1 protein modified form promotes the reaction [YBX1 protein binds to EP300 protein]] which binds to ABCB1 promoter]; kang-lai-te inhibits the reaction [Cisplatin results in increased expression of ABCB1 mRNA]; kang-lai-te inhibits the reaction [Cisplatin results in increased expression of ABCB1 protein]; Omeprazole promotes the reaction [Cisplatin results in increased expression of ABCB1 protein]
